# Generated by ReviewAid
Filename,Title,Author,Year,Confidence,Reason for Inclusion
1-s2.0-S0022510X21003166-main.pdf,Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic,Gerd Haga Bringeland,2021,0.95,"The paper focuses on adults (RRMS patients over 18 years) receiving natalizumab, evaluating wearing-off symptoms during standard interval dosing (SID) and extended interval dosing (EID), which aligns with the intervention criteria. The outcomes relate to Multiple Sclerosis (MS) symptoms, meeting the outcomes criterion. Thus, it meets all specified inclusion criteria."
1-s2.0-S221103482100612X-main.pdf,Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection,Landi D,2021,0.95,"The paper focuses on the safety of Natalizumab infusion in adults with Multiple Sclerosis (pwMS) during active SARS-CoV-2 infection, which aligns with the specified Population (Adults), Intervention (Natalizumab, SID, EID), and Outcomes (MS) criteria. The study population is adults with MS, the intervention is Natalizumab (included), and the outcomes relate to MS safety during SARS-CoV-2 infection."
1-s2.0-S1878747924000370-main.pdf,Commentary Extended interval dosing of natalizumab: More evidence in support,Karlo Toljan,2024,0.95,"The paper focuses on natalizumab (intervention) in adults (population) comparing standard interval dosing (SID) and extended interval dosing (EID), with outcomes related to multiple sclerosis (MS). It meets all inclusion criteria for population, intervention, and outcomes, and includes a comparison between the two dosing regimens."
10.1007@s00415-014-7574-6.pdf,LETTER TO THE EDITORS Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report,Maria SepuÂ´lveda,2014,0.95,"The paper is a case report of a 43-year-old adult with relapsing-remitting multiple sclerosis (MS) treated with natalizumab, who developed immune reconstitution inflammatory syndrome (IRIS)-like exacerbation after natalizumab withdrawal. The population (adults) and intervention (natalizumab) match the inclusion criteria, and the outcome (MS) is relevant. The paper provides detailed clinical and imaging data on the condition, meeting the systematic review criteria."
"A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis_Author links open overlay panel_Thomas Mathew a_, _Vikram Kamath b_, _Saji K John a_, _M Netravat.pdf",A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis,Thomas Mathew,2022,0.95,"The paper focuses on natalizumab (matching the intervention inclusion criteria) in adults with multiple sclerosis (matching population inclusion criteria). It reports efficacy and safety outcomes relevant to MS, with no exclusion of the intervention or population that would disqualify it."
